To further understand the role of canonical and non-canonical EZH2 associated pathways in chemotherapy resistance and prognosis, we investigated the correlation between the key components of two EZH2 pathways EZH2-H3K27Me3 and pAkt1-pS21EZH2 independently and in combination to the clinical outcomes of ovarian cancer patients. This evidence concerns the gene EZH2 and ovarian carcinoma.